CTOs on the Move

La Jolla Pharmaceutical

www.lajollapharmaceutical.com

 
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of ...
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Protalix BioTherapeutics , Inc.

Protalix BioTherapeutics , Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Fresh Tracks Therapeutics

Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company focused on transforming patient lives through the development of innovative and ground-breaking prescription therapeutics.

Immediate Pharmaceutical Services

Immediate Pharmaceutical Services is a Avon Lake, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.

Vit-Best

Vit Best Nutrition is a fully integrated contract manufacturer for the Nutritional Supplement Industry, offering a wide range of production capabilities for tablets, capsules, and powders.